Publications by authors named "J Hyams"

Claim this Profile
E
Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial.
Jess L Kaplan, Athos Bousvaros, Dan Turner, Marla Dubinsky, Amy Larkin, Jeffrey S Hyams

Lancet Gastroenterol Hepatol· February 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study.
Dan Turner, Kathleen G Lomax, Gigi Veereman, Anne M Griffiths, Jaroslaw Kierkuś, Jeffrey S Hyams

Inflamm Bowel Dis· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Timing is Everything: Lessons Learned for Building Microbiome-Based Models in Pediatric Crohn's Disease.
Charlotte M Verburgt, Katherine A Dunn, Joseph P Bielawski, Anthony R Otley, Melvin B Heyman, Jeffrey S Hyams

Inflamm Bowel Dis· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reshaping study design for faster extrapolation-based drug approval in pediatric inflammatory bowel diseases: An ESPGHAN-NASPGHAN position paper.
Dan Turner, Amit Assa, Mikkel Malham, Shira Yuval Bar-Asher, Carla Rayan, Jeffrey S Hyams

J Pediatr Gastroenterol Nutr· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short Ileal Microvillus Length Phenotype Associates with Progression from Inflammatory to Complicated Disease Behavior in Pediatric Crohn's Disease.
Yael Haberman, Tzipi Braun, Rebekah Karns, Courtney A Bartel, Erin Bonkowski, Jeffrey S Hyams

Inflamm Bowel Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis